Trusted Resource for Clinical Trials, Protocols & Progress
Understanding Audit Trails in EDC and eTMF Systems Understanding Audit Trails in EDC and eTMF Systems Introduction: Why Audit Trails Are Central to Clinical Data Integrity Audit trails are the backbone of data integrity in clinical research. They provide the documented evidence of every action taken on a data element, from creation to modification to…
Read More “Understanding Audit Trails in EDC and eTMF Systems” »
Pilot vs Pivotal Study Designs in BA/BE Trials: Regulatory Roles, Objectives, and Planning Understanding the Role of Pilot and Pivotal Studies in BA/BE Development Introduction: Why Differentiating Pilot and Pivotal Studies Matters In bioavailability and bioequivalence (BA/BE) development, the journey from formulation development to regulatory submission typically involves two key study types: the pilot study…
Ethics Committee Review for Vulnerable Populations in Clinical Trials Comprehensive Guide to Ethics Committee Review for Vulnerable Groups in Clinical Research Regulatory Expectations for Ethics Committee Review Ethics Committees (ECs), also known as Institutional Review Boards (IRBs), play a critical role in safeguarding vulnerable populations in clinical trials. Vulnerable groups — such as children, the…
Read More “Ethics Committee Review for Vulnerable Populations in Clinical Trials” »
Must-Know EDC Systems for Aspiring Data Managers Top EDC Platforms Every Future Clinical Data Manager Must Learn 1. Introduction: Why EDC Proficiency is Essential for Data Managers Electronic Data Capture (EDC) systems are the heart of modern clinical data management. From data entry to query management and database locking, EDC platforms control every critical step…
Read More “Must-Know EDC Systems for Aspiring Data Managers” »
SOP for Protocol Amendments and Regulatory Notifications { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.Clinicalstudies.in/SOP-for-Protocol-Amendments-and-Regulatory-Notifications” }, “headline”: “SOP for Protocol Amendments and Regulatory Notifications in Clinical Trials”, “description”: “A regulatory-compliant SOP detailing the step-by-step process for managing clinical trial protocol amendments and regulatory notifications as per ICH GCP, WHO, FDA, EMA, and…
Read More “SOP for Protocol Amendments and Regulatory Notifications” »
Expedited Programs for Oncology Trial Approvals Leveraging Expedited Programs for Oncology Trial Approvals Introduction to Expedited Regulatory Pathways Expedited regulatory programs aim to accelerate the development and approval of oncology drugs addressing serious or life-threatening conditions, particularly where there is an unmet medical need. In oncology, where time-sensitive treatment decisions can significantly impact patient outcomes,…
Read More “Expedited Programs for Oncology Trial Approvals” »
CAPA Documentation Best Practices Best Practices for CAPA Documentation in Clinical Trials Why CAPA Documentation Matters In the world of clinical research, a CAPA (Corrective and Preventive Action) that isn’t properly documented may as well not exist. Regulatory bodies like the FDA and EMA emphasize not only the resolution of issues but also the transparency,…
Integration of Finance Tools with CTMS Streamlining Budget Forecasting Through CTMS-Finance Integration Why Financial Forecasting Needs CTMS Integration In modern clinical trial operations, managing financials manually or in isolation from operational data leads to significant challenges. Disconnected tools often result in delayed budget forecasts, mismatched payment schedules, and non-compliance with regulatory expectations. Clinical Trial Management…
Security and Confidentiality in TMF Archiving Ensuring Security and Confidentiality in TMF Archiving Why TMF Security and Confidentiality Are Non-Negotiable Trial Master File (TMF) documents contain sensitive and proprietary data—including patient information, investigational product details, and regulatory correspondence. Improper handling or exposure of TMF records can lead to regulatory penalties, sponsor liability, and reputational harm….
Fast Track and Breakthrough Therapy for Rare Diseases Accelerating Rare Disease Therapies Through Fast Track and Breakthrough Designations The Need for Expedited Development in Rare Diseases Rare diseases—often debilitating, progressive, and life-threatening—affect millions worldwide, yet most lack approved treatments. Traditional drug development timelines spanning 10–15 years are incompatible with the urgent needs of rare disease…
Read More “Fast Track and Breakthrough Therapy for Rare Diseases” »
